Literature DB >> 2356567

Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices.

Y Kameyama1, N Okazaki, M Nakagawa, H Koshida, M Nakamura, M Gemba.   

Abstract

The addition of a new compound containing platinum, 254-S, an antineoplastic agent, to medium had no effect on p-aminohippurate (PAH) accumulation, gluconeogenesis, or potassium and ATP concentrations in rat kidney cortical slices at the concentrations tested, up to 10 mM. At 1 mM, cisplatin, used for comparison, significantly decreased all of these biochemical indices in the slices. Administration of 254-S at a low dose (10 mg/kg i.v.) to rats decreased the ability of the slices to accumulate PAH and to maintain the potassium concentration, without affecting levels of urea or creatinine in blood plasma. 254-S at a high dose (20 mg/kg i.v.) or cisplatin at 5 mg/kg (i.v.) also decreased these indices in the slices, and affected urea and creatinine in blood plasma. These results suggested that use of the renal slice technique gives data useful for the evaluation of the nephrotoxicity of 254-S, and that PAH accumulation and the potassium concentration in slices from rats treated with 254-S are indicators of nephrotoxic damage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2356567     DOI: 10.1016/0378-4274(90)90161-e

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  16 in total

1.  Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.

Authors:  Toru Ishibashi; Yoshitaka Yano; Takayoshi Oguma
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

2.  A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma.

Authors:  Yi-Fu He; Chu-Shu Ji; Bing Hu; Ping-Sheng Fan; Chang-Lu Hu; Feng-Shou Jiang; Jian Chen; Lei Zhu; Yi-Wei Yao; Wei Wang
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

3.  Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.

Authors:  F Oshita; M Ohe; T Honda; S Murakami; T Kondo; H Saito; K Noda; K Yamashita; Y Nakayama; K Yamada
Journal:  Br J Cancer       Date:  2010-10-12       Impact factor: 7.640

4.  cis-Diammine(glycolato-κO,O)platinum(II).

Authors:  Qing-Kun Wang; Shao-Ping Pu; Yan-Wei Cong; Yong-Nian Li; Chun-Fang Luan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-11-28

5.  Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial.

Authors:  Jin-Ji Yang; Qing Zhou; Ri-Qiang Liao; Yi-Sheng Huang; Chong-Rui Xu; Zhen Wang; Bin-Chao Wang; Hua-Jun Chen; Yi-Long Wu
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

6.  Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma.

Authors:  Toru Fujioka; Toshiaki Yasuoka; Masae Koizumi; Hiroki Tanaka; Hisashi Hashimoto; Motoo Nabeta; Koji Koizumi; Yuko Matsubara; Katsuyuki Hamada; Keiichi Matsubara; Tomihiro Katayama; Akihiro Nawa
Journal:  Mol Clin Oncol       Date:  2012-09-25

7.  Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.

Authors:  Satoshi Osawa; Takahisa Furuta; Ken Sugimoto; Takashi Kosugi; Tomohiro Terai; Mihoko Yamade; Yasuhiro Takayanagi; Masafumi Nishino; Yasushi Hamaya; Chise Kodaira; Takanori Yamada; Moriya Iwaizumi; Kosuke Takagaki; Ken-ichi Yoshida; Shigeru Kanaoka; Mutsuhiro Ikuma
Journal:  BMC Cancer       Date:  2009-11-22       Impact factor: 4.430

8.  Nedaplatin: a cisplatin derivative in cancer chemotherapy.

Authors:  Muneaki Shimada; Hiroaki Itamochi; Junzo Kigawa
Journal:  Cancer Manag Res       Date:  2013-05-08       Impact factor: 3.989

9.  Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer.

Authors:  Keiichi Jingu; Kenji Nemoto; Haruo Matsushita; Chiaki Takahashi; Yoshihiro Ogawa; Toshiyuki Sugawara; Eiko Nakata; Yoshihiro Takai; Shogo Yamada
Journal:  BMC Cancer       Date:  2006-03-04       Impact factor: 4.430

10.  Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.

Authors:  H Tsuda; Y Hashiguchi; S Nishimura; M Miyama; S Nakata; N Kawamura; S Negoro
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.